Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
By Guest Contributor | May 29, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
IP Explained: Intellectual property system working to combat COVID-19
By Megan Van Etten | May 28, 2020
Biopharmaceutical companies are working around the clock to research and develop COVID-19 vaccines and treatments. Intellectual property (IP) has enabled robust research collaboration among...
Read More
Guest Post: What will we learn from COVID-19?
By Guest Contributor | May 27, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
It’s a good thing pharmaceutical manufacturing supply chains are spread out around the world
By Nicole Longo | May 21, 2020
The biopharmaceutical industry is committed to ensuring Americans and people around the world have access to the medicines they need. As a result, companies do everything they can to make sure...
Read More
New rule makes it harder for patients to lower their out-of-pocket costs
By Holly Campbell | May 20, 2020
In the midst of increased financial insecurity for Americans due to the COVID-19 pandemic, it is shocking the Administration finalized a policy change in the 2021 Notice of Benefit and Payment...
Read More
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
By Richard Moscicki, M.D. | May 18, 2020
This week is Clinical Trials Awareness Week — an event to recognize the importance of clinical trials, raise public awareness of clinical research and honor clinical research professionals and...
Read More
Setting up a pharmaceutical manufacturing supply chain is a complex and lengthy process
By Nicole Longo | May 14, 2020
Did you know that biopharmaceutical manufacturers must begin setting up the manufacturing supply chain for a medicine years before that medicine is even approved for use by patients? That’s a fact...
Read More
PhRMA submits comments to CMS on policy changes for in-home care under Part B during COVID-19
By Nicole Longo | May 6, 2020
The COVID-19 pandemic has caused a number of disruptions in our health care system, one of which is the ability for seniors to access their infused or injected Part B medicines normally...
Read More
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
By Tom Wilbur | May 4, 2020
The U.S. biopharmaceutical industry depends on reliable intellectual property (IP) protections to promote the development of new breakthrough treatments and cures for patients. Strong IP...
Read More
The continued imperative to protect U.S. innovation worldwide
By Chris Moore | April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
